Mechanism of Action
Intepirdine (RVT-101) is an orally administered, potent antagonist of the 5HT6 receptor. Blocking the 5HT6 receptor promotes the release of acetylcholine, an essential neurotransmitter needed for normal cognition and function. Together, intepirdine and donepezil may work to preserve acetylcholine and improve the cognition and function of patients with mild to moderate Alzheimer’s disease.
We are developing intepirdine for adjunctive use with donepezil, a drug that inhibits cholinesterase from breaking down acetylcholine. Cholinesterase inhibitors, like donepezil, are the only class of drugs approved by the FDA for the treatment of patients with mild to moderate Alzheimer’s disease.
Mechanism of Action with Donepezil
When 5HT6 receptor antagonists are used together with cholinesterase inhibitors, these agents can work together to increase the concentration of acetylcholine through complementary mechanisms without worsening the side effects associated with cholinesterase inhibitors, such as nausea and vomiting.
A global phase 3 clinical research study evaluating intepirdine
(RVT-101) for mild-to-moderate Alzheimer’s Disease*
*Intepirdine (RVT-101) is an investigational new drug candidate and is not approved for any indication in any markets.